Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2015

View Archived Issues

Corbus Pharmaceuticals receives IND clearance from FDA to begin phase II trials of Resunab

Canagliflozin provides greater reduction in A1C and body weight than sitagliptin

Phase I results reported on novel peptide deformylase inhibitor, IDP-73152 mesylate

HM-10560A found safe in growth hormone deficiency patients

AGTC files IND to study gene therapy for X-linked retinoschisis

CureVac patents new rabies vaccine

LG Life Sciences discloses necrosis and apoptosis inhibitors

Shanghai Bioduro Biologics patent describes FFAR1 agonists

Allergen completes series B financing round to advance drug development portfolio

Taiho Pharmaceutical divulges novel EGFR inhibitors

Toyama Chemical reports development of antifungal agents

BriaCell Therapeutics submits phase I/II protocol to the FDA

GlaxoSmithKline describes second-generation HIV-1 maturation inhibitor

Galectin Therapeutics to conduct phase II trial of GR-MD-02 in NASH

Thyroid hormone receptor activation induces white adipose tissue conversion

Kura Oncology enters into agreement with Janssen Pharmaceutica for tipifarnib

Neuralstem reports topline results from phase II NSI-566 trial

Endo makes proposal to acquire Salix

NIH grant supports RetroVirox's work in HIV

Evotec and Second Genome establish microbiome discovery and development collaboration

Novartis's LCZ-696 awarded priority review by Health Canada

Epizyme regains ex-Japanese rights to EPZ-6438 from Eisai

Meiji Seika Pharma discontinues development of ME-3301

AB Science reports results from phase Ib/II study of masitinib in triple-negative breast cancer

FDA accepts resubmitted NDA for daclatasvir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...